Evidence map›Paper›PMID 40240779›Full record

ArticleScientific reports2025

Celastrol loaded nanocomplex for painless tumor therapy via YAP inhibition.

Zhaokun Hao, Yuming Zhou, Yuqiang Zhang, Danyang Wang, Yiying Wei, Xiaopu Ji, Wan Ru Sun, Pingyu Wang, YouJie Li, Irene Bautista Lopez and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhaokun Hao *Institute of Rehabilitation Medicine, School of Rehabilitation Medicine, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Yuming Zhou *Department of Clinical Laboratory, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264100, People's Republic of China.
Yuqiang ZhangDepartment of Clinical Laboratory, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264100, People's Republic of China.
Danyang WangInstitute of Rehabilitation Medicine, School of Rehabilitation Medicine, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Yiying WeiInstitute of Rehabilitation Medicine, School of Rehabilitation Medicine, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Xiaopu JiInstitute of Rehabilitation Medicine, School of Rehabilitation Medicine, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Wan Ru SunInstitute of Rehabilitation Medicine, School of Rehabilitation Medicine, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Pingyu WangKey Laboratory of Tumor Molecular Biology, Binzhou Medical University, Yantai, 264003, People's Republic of China.
YouJie LiKey Laboratory of Tumor Molecular Biology, Binzhou Medical University, Yantai, 264003, People's Republic of China.
Irene Bautista LopezNanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006, Vitoria-Gasteiz, Spain.
José Luis PedrazNanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006, Vitoria-Gasteiz, Spain.
Murugan RamalingamNanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006, Vitoria-Gasteiz, Spain. murugan.ramalingam@ehu.eus.
Shuyang XieShandong Laboratory of Advanced Materials and Green Manufacturing, Yantai, 264000, People's Republic of China. shuyangxie@aliyun.com.
Ranran WangInstitute of Rehabilitation Medicine, School of Rehabilitation Medicine, Binzhou Medical University, Yantai, 264003, People's Republic of China. wangrr@bzmc.edu.cn.

Funding

ICTS ″NANBIOSIS″, in particular by the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials and Nanomedicine CIBER-BBNScience Fund of Shandong Laboratory of Advanced Materials and Green Manufacturing at Yantai AMGM2021F03Science Fund of Shandong Laboratory of Advanced Materials and Green Manufacturing at Yantai AMGM2023F16Shandong Province Taishan Scholar Project ts201712067State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology CRE-24-C003The Education Department of Shandong Province 2022KJ091The National Natural Science Foundation of China 51903015The National Natural Science Foundation of China 81772281The Shandong Science and Technology Committee ZR2020KH015The Shandong Science and Technology Committee ZR2022LSW002
6 · The paper itself

Abstract

Cancer-related pain is prevalent and severely impairs patients' quality of life. However, conventional cancer therapies primarily target tumor cell destruction, often overlooking the management of cancer pain. Thus, there is an immediate necessity to develop therapeutic agents that can both suppress tumor growth and alleviate cancer pain. In this study, we report a celastrol (CEL)-based nanocomposites (PDA-BSA-MnO

Indexed as

Adaptor Proteins, Signal TransducingCancer PainNanocompositesNeoplasmsTranscription FactorsTriterpenesAnimalsCell Line, TumorHumansImmunotherapyMicePentacyclic TriterpenesTumor MicroenvironmentYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingcelastrolPentacyclic TriterpenesTranscription FactorsTriterpenesYAP1 protein, humanYAP-Signaling ProteinsCancer pain supressionCelastrolImmunotherapyNanocompositeYAP Inhibition

Identifiers

PMID40240779
PMCPMC12003811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.